{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05341947",
            "orgStudyIdInfo": {
                "id": "IIT2019-23-Rudnick-ATC"
            },
            "organization": {
                "fullName": "Cedars-Sinai Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma",
            "officialTitle": "A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma",
            "therapeuticArea": [
                "Other"
            ],
            "study": "activated-autologous-t-cells-against-glioma-cancer-stem-cell-antigens-for-patients-with-recurrent-glioblastoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-24",
            "studyFirstSubmitQcDate": "2022-04-21",
            "studyFirstPostDateStruct": {
                "date": "2022-04-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Jeremy Rudnick, M.D",
                "investigatorTitle": "Co-Director, Neuro-Oncology",
                "investigatorAffiliation": "Cedars-Sinai Medical Center"
            },
            "leadSponsor": {
                "name": "Jeremy Rudnick, M.D",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Kairos Pharma",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxicities, the number of serious adverse events, and treatment-related toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of overall survival, rate of progression-free survival, health-related quality of life parameters, overall response rate, immune response, and tumor stem cell antigen expression."
        },
        "conditionsModule": {
            "conditions": [
                "Recurrent Glioblastoma"
            ],
            "keywords": [
                "glioma",
                "brain tumor",
                "glioblastoma",
                "neurosurgery",
                "surgical resection",
                "Complete resection of tumor",
                "extent of resection",
                "maximal safe resection",
                "neuropathology",
                "astrocytoma",
                "ependymoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Activated T cells",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: Activated T cells"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Activated T cells",
                    "description": "Activated T cells (ATC) administered intravenously at one timepoint",
                    "armGroupLabels": [
                        "Activated T cells"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Grade 3 or higher toxicities, number of serious adverse events, and the number of treatment-related toxicities to find the maximum tolerated dose",
                    "description": "Recorded and graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAEs) Version 5",
                    "timeFrame": "From start of study treatment until End of Study, an average of 2 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Survival (OS)",
                    "timeFrame": "From date of enrollment to date of death of any cause or withdrawal of consent, whichever came first. Assessed up to 3 years."
                },
                {
                    "measure": "Progression-Free Survival (PFS)",
                    "timeFrame": "From start of study treatment, until confirmation of disease progression or withdrawal of consent, whichever came first. Assessed up to 3 years."
                },
                {
                    "measure": "Health-related quality of life parameters",
                    "description": "Measured by change in the Functional Assessment of Cancer Therapy - Brain (FACT-Br) survey score. The FACT-Br total score has a range of 0-200 and higher scores indicate better quality of life",
                    "timeFrame": "From baseline visit to End of Study, an average of 2 months"
                },
                {
                    "measure": "Overall Response Rate (ORR)",
                    "description": "Percentage of patients showing either partial response or complete response, in patients with subtotal resection, will be measured using Magnetic Resonance Imaging (MRI) and Immunotherapy Response Assessment in Neuro-Oncology (iRANO) Response Criteria",
                    "timeFrame": "From pre-study Brain MRI through study completion or withdrawal of consent, whichever came first. Assessed up to 3 years."
                },
                {
                    "measure": "Immune Response",
                    "description": "Assessed by cytotoxic T cell activity in vitro pre- vs post-infusion.",
                    "timeFrame": "At Visit 1, Post-immunotherapy infusion follow-up Day 14, and Survival follow-up Month 2"
                },
                {
                    "measure": "Tumor stem cell antigen expression",
                    "description": "Assessed by quantitative PCR for expression of CD133, housekeeping genes, and tumor associated antigens (including HER2, TRP-2, gp100, MAGE-1, IL13R\u03b12, AIM-2).",
                    "timeFrame": "At Baseline visit and at time of recurrence. Assessed up to 3 years."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Recurrent glioblastoma\n* HLA-A1 and HLA-A2 positive\n* Complete resection of tumor\n\nExclusion Criteria:\n\n* Clinically significant pulmonary, cardiac or other systemic disease\n* Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed.\n* Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition.\n* Known history of Hepatitis B or Hepatitis C\n* Allergy to Dimethyl sulfoxide (DMSO)\n* Allergy to gentamicin",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trial Navigator",
                    "role": "CONTACT",
                    "phone": "310-423-2133",
                    "email": "cancer.trial.info@cshs.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jeremy Rudnick, MD",
                    "affiliation": "Cedars-Sinai Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cedars-Sinai Medical Center",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trial Navigator",
                            "role": "CONTACT",
                            "phone": "310-423-2133",
                            "email": "cancer.trial.info@cshs.org"
                        },
                        {
                            "name": "Jethro Hu, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Justin Darrah, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Ray Chu, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Chirag Patil, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005909",
                    "term": "Glioblastoma"
                },
                {
                    "id": "D000005910",
                    "term": "Glioma"
                },
                {
                    "id": "D000012008",
                    "term": "Recurrence"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000001254",
                    "term": "Astrocytoma"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9020",
                    "name": "Glioma",
                    "asFound": "Glioma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "asFound": "Recurrent",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9019",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5209",
                    "name": "Brain Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7965",
                    "name": "Ependymoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M4561",
                    "name": "Astrocytoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T2519",
                    "name": "Glioma",
                    "asFound": "Glioma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2518",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2093",
                    "name": "Ependymoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}